title: IgM antibodies in renal transplantation.
abstract: A prospective final crossmatch with patient serum and donor lymphocytes using the complement-dependent cytotoxicity assay to identify any performed anti-donor antibody is required for kidney transplantation. The presence of pre-existing antibody may lead to hyperacute rejection of the transplanted kidney. Certain anti-donor antibodies have previously been shown to be ineffective in promoting hyperacute rejection, such as IgM autoantibodies and non-specific IgM lymphocytotoxic antibodies. In this report, we present evidence that IgM HLA alloantibody specific to the donor does not lead to hyperacute rejection and produces graft survival results equivalent to transplants with negative pre-transplant final crossmatches. Forty-eight (48) of 402 patients transplanted over and 8 yr period were transplanted across a positive final crossmatch due to IgM antibodies alone. Three patients exhibited IgM autoantibodies and 26 patients demonstrated non-specific IgM antibodies to lymphocytes. In 15 patients, following a detailed serum screening analysis, a significant correlation (r > 0.9, p < 0.001) was observed between HLA Class I antigens and the presence of corresponding IgM alloantibodies. Five of these patients were subsequently transplanted despite a positive final crossmatch that was clearly demonstrated to be the result of IgM alloantibody to donor HLA Class I specificities. All of these patients continue to have graft function. These results suggest that hyperacute rejection is not mediated by any type of IgM antibody to donor lymphocytes and that kidney transplantation when only IgM antibody is present against donor lymphocytes represents a reasonable opportunity for a safe transplant and successful long-term graft survival.
authors.affiliation: Immunological Associates of Denver, Columbia P/SL Medical Center, PorterCare Hospital, CO 80206, USA.
authors.forename: R T
authors.initials: RT
authors.lastname: McCalmon
authors.forename: G N
authors.initials: GN
authors.lastname: Tardif
authors.forename: M A
authors.initials: MA
authors.lastname: Sheehan
authors.forename: K
authors.initials: K
authors.lastname: Fitting
authors.forename: W
authors.initials: W
authors.lastname: Kortz
authors.forename: I
authors.initials: I
authors.lastname: Kam
mesh_terms: D001323:Autoantibodies / Q000032:analysis*; D004229:Dithiothreitol; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000032:analysis*; D006650:Histocompatibility Testing; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis*; D007518:Isoantibodies / Q000032:analysis*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D014181:Transplantation Immunology / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007518:Isoantibodies; D004229:Dithiothreitol